Paul Pavlou has been named as the dean of C. T. Bauer College of Business at the University of Houston. Courtesy of UH

Earlier this year, the University of Houston named a new dean for its C.T. Bauer College of Business. Paul Pavlou officially started his position on July 1, and, even though he has only a few days under his belt at UH, the new dean has a long career in education.

Most recently, Pavlou served as senior associate dean at Temple University within its business program and specializing in data analytics for business. Pavlou also has ties to Houston, as he received his bachelor's from Rice University after receiving a Fulbright Scholarship.

"My life was transformed by higher education," Pavlou says. "So, I feel the need to give back in terms of helping other students — especially of modest means like myself to do well in life and get a good job."

Pavlou has a lot on his plate entering the fall semester. He plans to continue enhancing the college's programs and faculty, while also continue the school's effort to bring in innovation and industry.

The new dean spoke with InnovationMap about what all he sees in Bauer's future.

InnovationMap: How has the first few days on the job been?

Paul Pavlou: So far it's been very exciting. There's so many opportunities for the Bauer College in innovation and technology in new areas that we're considering such health care, analytics, some of the existing areas in energy. So, the goal in my first few days is to talk to as many stakeholders as possible. Try to get to know our existing practices internally, what the opportunities are in the city, and of course, broadly, nationally, internationally. And accordingly, the plan is to see how we can focus on this needs of the industry, how we can create cutting edge programs and prepare the next generation of the workforce, obviously for the city of Houston or the state of Texas nationally and even that globally.

IM: What are some things on your plate that you hope to bring to the college?

PP: In general, one of the areas that I'd like to see us moving into as a college is the digital learning online and how we can do that in a way that it's convenient and flexible for students. Also at the same time, not only maintain the quality of traditional instruction, but also using technology intelligently to provide an even higher quality, more interactive experience for students.

The second thing that I'm very passionate about as well as the notion of experiential learning. I think students should learn from experience and learn by doing. So I would like to see how we can improve this at this college. I'm very happy to report that Bauer has very strong connections to industry, but I would like to make it an even a very strong proposition for the entire college — making sure that, you know, different courses that have an experiential component such as project or working closely with industry.

IM: How is Bauer focusing on the needs the city has for an emerging workforce?

PP: I think increasingly I find and identify more of the city's needs, but I think one of them is the idea of the analytics space and how to use the data. And that's across the board. I talk to people in health care and they say that health care analytics and using data in hospitals is a very important aspect.

More broadly, cutting edge technology is something that is very important not only the city of Houston but beyond. So. we're discussing this idea of artificial intelligence, and how we can play a role in this in a very important emerging area.

One of the things that I would like to see more of is for the University of Houston to work more closely with the business community. We're trying to develop partnerships with the greater Houston partnership and to see what they need as an industry, perhaps for the next generation of workforce.

IM: What role do you see the school playing in the city's innovation ecosystem?

PP: I think we can play a multiple roles. We're an educational organization, so we train the students. We want make sure that through our degrees and offerings have executive programs, and that we satisfy the need for competence and skills needed. And that's why I want us to be on the cutting edge, not only now but in the next five or 10 years.

Second, through our research and through our connections to industry, I want us to be cutting edge in terms of projects and basic research we can actually provide, whether it's analytics, artificial intelligence, or energy. Through our centers and our research, we have world class research faculty in the college. I want us to be out there and to start with the major challenges and help them.

IM: How is the college working with other programs within the university?

PP: One thing I'd like to specify, is that Bauer is obviously a college of business, but I want to take a very broad, multidisciplinary perspective and be very collaborative with the college of medicine, engineering, and nursing. And the idea is to be more open in terms of partnerships with different areas that innovation and new ideas may come into play and provide the business and entrepreneurship components to bring these ideas to market.

------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from leaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”